Market Overview

Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028


NEW YORK, March 6, 2020 /PRNewswire/ --

Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028


Read the full report:

Psoriatic arthritis (PsA) is a chronic form of arthropathy commonly associated with psoriasis.Patients are evaluated on five disease domains: peripheral arthritis, axial disease, enthesitis, dactylitis, and nail and skin involvement.

Due to the heterogeneity of clinical symptoms, PsA can be difficult to diagnose and treat.

Current therapies for disease management include conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), injectable immuno-suppressants and oral small molecule therapies.Of these, intravenous and subcutaneous therapies targeting tumor necrosis factor (anti-TNFs) have been the gold standard of care for almost 20 years.

However, other mechanisms of action have gained traction in recent years.Over the forecast period, market growth is expected to be driven primarily by the approval and launch of five pipeline therapies.

However, this growth will likely be curtailed by the erosion of branded agents sales by biosimilars and generics in the second half of the forecast period.

Key Highlights
- The greatest drivers of growth in the global PsA market include the launch of five new pipeline therapies during the forecast period and a steadily climbing diagnosed prevalence in many 7MM countries.
- The main barriers to growth in the PsA market include low diagnostic and treatment rates as well as low patient compliance and persistence.
- Among the late-stage pipeline products, two are injectable anti-interleukin therapies and three are oral Janus Kinase (JAK) inhibitors.
- The most important unmet needs in the PsA market are increased access to therapies as well as therapies that can target the multiple disease domains.


- Which unmet needs are limiting the treatment of PsA in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan)?
- What strategies can the pharmaceutical industry employ to increase treatment rates for PsA? How should these strategies differ across different geographical markets?
- What effect will the launch of biosimilars and generics have on the sales of branded agents? What can drug manufacturers do in order to ensure the success of their biosimilars?
- What are the main R&D trends in the PsA market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?

- Overview of PsA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline PsA market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting PsA therapeutics sales in the 7MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global PsA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global PsA therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PsA market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global PsA therapeutics market from 2018-2028.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare:
US: (339)-368-6001
Intl: +1 339-368-6001

Cision View original content:

SOURCE Reportlinker

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at